XML 16 R4.htm IDEA: XBRL DOCUMENT v3.19.1
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2019
Mar. 31, 2018
Revenues:    
Total revenues $ 12,290 $ 8,865
Cost of sales (3,898) (4,071)
Gross profit 8,392 4,794
Operating expenses:    
Selling, general and administrative 8,543 6,488
Research and development 405 87
Total operating expenses 8,948 6,575
Loss from operations (556) (1,781)
Other income (expense):    
Interest expense, net (603) (663)
Other income, net 630
Total other income (expense), net 11,889 (1,732)
Total net income (loss) including noncontrolling interests 11,333 (3,513)
Net loss attributable to noncontrolling interests 25
Net income (loss) attributable to Harrow Health, Inc. $ 11,358 $ (3,513)
Basic net income (loss) per share of common stock $ 0.46 $ (0.17)
Diluted net income (loss) per share of common stock $ 0.43 $ (0.17)
Weighted average number of shares of common stock outstanding, basic 24,841,386 20,949,199
Weighted average number of shares of common stock outstanding, diluted 26,589,695 20,949,199
Melt Pharmaceuticals [Member]    
Other income (expense):    
Investment gain from and equity net Loss $ 5,525
Surface Pharmaceuticals [Member]    
Other income (expense):    
Investment gain from and equity net Loss (243)
Eton Pharmaceuticals [Member]    
Other income (expense):    
Investment gain from and equity net Loss 6,580 (1,069)
Product Sales, Net [Member]    
Revenues:    
Total revenues 12,283 8,855
License Revenues [Member]    
Revenues:    
Total revenues $ 7 $ 10